Predictive Markers to Personalize Medicine for Malignant Glioma

恶性胶质瘤个性化医疗的预测标记

• 批准号: 8588569
• 负责人: KENNETH D ALDAPE
• 金额: $ 23.7万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8588569
• 关键词: Clinical; Complex; Development; Diagnostic; Diagnostic tests; Disease; Genomics; Heterogeneity; Knowledge; Malignant Glioma; Malignant neoplasm of brain; Medicine; Molecular; Outcome; Patients; Prognostic Marker; Translating; improved; molecular marker; novel; response; treatment response

Progress in the treatment of patients with GBM has been limited by the ability to identify those subsets of patients that will respond to a particular therapy. GBM is a heterogeneous disease with a diverse molecular makeup and selecting patients for appropriate novel agents is needed to improve outcomes.. Successful development of the molecular predictors proposed in this project will translate into personalization of treatment and better patient survival.

GBM患者的治疗进展受到鉴定这些亚群的能力的限制。 对特定疗法有反应的病人GBM是一种异质性疾病，具有不同的分子 需要为患者补充和选择合适的新型药物以改善结果。成功 在这个项目中提出的分子预测的发展将转化为个性化的 治疗和更好的患者生存率。